-
公开(公告)号:WO2022068247A1
公开(公告)日:2022-04-07
申请号:PCT/CN2021/097796
申请日:2021-06-02
申请人: 广州恩宝生物医药科技有限公司
IPC分类号: A61K39/235 , A61K39/295 , A61P31/20 , A61K2039/70 , A61K39/12 , C12N2710/10334
摘要: 本发明公开了一种腺病毒四价疫苗,其包括复制缺陷型人3型腺病毒、4型腺病毒、7型腺病毒和55型腺病毒,所述复制缺陷型人3型腺病毒、4型腺病毒、7型腺病毒和55型腺病毒的E1、E3基因缺失,E4基因的部分编码框置换为人5型腺病毒E4基因的相应编码框。本发明的腺病毒四价疫苗能够有效刺激机体产生体液免疫应答和细胞免疫应答,产生高效价的特异性中和抗体,用于预防病原体的感染。
-
公开(公告)号:WO2022192278A2
公开(公告)日:2022-09-15
申请号:PCT/US2022/019371
申请日:2022-03-08
申请人: CITY OF HOPE
发明人: WANG, Edward , YUE, Er
IPC分类号: C12N15/86 , A61K38/19 , A61P35/00 , A61K35/761 , A61K39/12 , C12N2710/10332 , C12N2710/10334 , C12N2710/10343 , C12N2830/008
摘要: Provided herein are, inter alia, viral compositions and methods of using the same. The viral compositions comprise a virus including a nucleic acid encoding a MUC16 promoter operably linked to an essential viral gene. The compositions provided herein are contemplated to be particularly useful for treating CA-125 expressing cancers.
-
3.
公开(公告)号:WO2022003083A1
公开(公告)日:2022-01-06
申请号:PCT/EP2021/068124
申请日:2021-07-01
申请人: REITHERA SRL
IPC分类号: C07K14/075 , C12N15/861 , C07K14/005 , C12N15/86 , C12N2710/10321 , C12N2710/10323 , C12N2710/10334 , C12N2710/10343 , C12N2770/20034 , C12N7/00
摘要: The present invention relates to novel adenovirus strains with a high immunogenicity and very low pre-existing immunity in the general human population. The absence of detectable neutralizing antibodies is due to novel hypervariable regions in the adenoviral capsid protein hexon. The present invention provides nucleotide and amino acid sequences of these novel adenovirus strains, as well as recombinant viruses, virus-like particles and vectors based on these strains. Further provided are pharmaceutical compositions and medical uses in the therapy or prophylaxis of a disease, and methods for producing an adenovirus or virus-like particles utilizing the novel sequences, recombinant viruses, virus-like particles and vectors.
-
公开(公告)号:WO2021139147A1
公开(公告)日:2021-07-15
申请号:PCT/CN2020/106400
申请日:2020-07-31
申请人: 广州恩宝生物医药科技有限公司
IPC分类号: A61K39/235 , A61K39/295 , A61P31/20 , A61K2039/70 , A61K39/12 , C12N2710/10334
摘要: 一种腺病毒二价疫苗,其包括复制缺陷型人4型腺病毒和复制缺陷型人7型腺病毒。所述复制缺陷型人4型腺病毒、7型腺病毒的E1、E3基因缺失,E4基因的部分编码框置换为人5型腺病毒E4基因的相应编码框。该腺病毒二价疫苗能够有效刺激机体产生体液免疫应答和细胞免疫应答,产生高效价的特异性中和抗体,用于预防病原体的感染。
-
-
-